✦ LIBER ✦

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer

✍ Scribed by Heigener, D.F.; Deppermann, K.M.; Pawel, J.v.; Fischer, J.R.; Kortsik, C.; Bohnet, S.; Eiff, M.v.; Koester, W.; Thomas, M.; Schnabel, P.A.; Reck, M.

Book ID: 121836187
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 518 KB
Volume: 84
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2014.01.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter Phase II Trial of Carboplati

Multicenter Phase II Trial of Carboplatin/Vinorelbine in Elderly Patients with Advanced Non–Small-Cell Lung Cancer–Efficacy and Impact on Quality of Life: Groupe Français de Pneumo-Cancérologie Study 9902

✍ Hervé LeCaer; Jean Yves Delhoume; Pascal André Thomas; Henri Berard; Dominique P 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 525 KB

Randomized open-label non-comparative mu

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

✍ Auliac, J.B.; Chouaid, C.; Greiller, L.; Monnet, I.; Le Caer, H.; Falchero, L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 484 KB

9035 POSTER A National, Multi Center, Ra

9035 POSTER A National, Multi Center, Randomized, Open-label, Phase II Study of Erlotinib Versus Gemcitabine (GEM) Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N2 Non-small-cell Lung Cancer (NSCLC) Patients (pts) With Activating EGFR Mutations (C-TONG 1103)

✍ Zhonq, W.; Wu, Y.; Wang, C.; Mao, W.; Xu, L.; Cheng, Y.; Yang, X.; Chen, K. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB